| Colorectal Cancer Treatments and Studies | Lifetime | 3 | PS 1 | 99.98 |
| Gastric Cancer Management and Outcomes | Lifetime | 6 | PS 1 | 99.97 |
| Cancer Treatment and Pharmacology | Lifetime | 8 | PS 1 | 99.95 |
| Genetic factors in colorectal cancer | Lifetime | 8 | PS 1 | 99.91 |
| Cancer Genomics and Diagnostics | Lifetime | 36 | PS 1 | 99.89 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 24 | PS 1 | 99.71 |
| Lung Cancer Treatments and Mutations | Lifetime | 91 | PS 1 | 99.72 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 139 | PS 1 | 99.64 |
| HER2/EGFR in Cancer Research | Lifetime | 63 | PS 1 | 99.66 |
| Colorectal and Anal Carcinomas | Lifetime | 56 | PS 1 | 99.42 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 61 | PS 1 | 99.55 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 145 | PS 1 | 99.51 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 127 | PS 1 | 99.44 |
| Melanoma and MAPK Pathways | Lifetime | 73 | PS 1 | 99.14 |
| Fibroblast Growth Factor Research | Lifetime | 85 | PS 1 | 98.14 |
| Colorectal Cancer Surgical Treatments | Lifetime | 259 | PS 1 | 98.62 |
| Esophageal Cancer Research and Treatment | Lifetime | 264 | PS 1 | 98.45 |
| Cancer Research and Treatments | Lifetime | 343 | PS 1 | 98.00 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 951 | PS 1 | 98.55 |
| Economic and Financial Impacts of Cancer | Lifetime | 230 | PS 1 | 97.26 |
| Advanced Breast Cancer Therapies | Lifetime | 250 | PS 1 | 97.91 |
| CAR-T cell therapy research | Lifetime | 931 | PS 1 | 97.63 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 969 | PS 1 | 97.73 |
| Metastasis and carcinoma case studies | Lifetime | 954 | PS 2 | 94.43 |
| Neutropenia and Cancer Infections | Lifetime | 756 | PS 1 | 94.31 |
| Cancer Mechanisms and Therapy | Lifetime | 848 | PS 1 | 92.58 |
| Kruppel-like factors research | Lifetime | 429 | PS 1 | 92.51 |
| Biosimilars and Bioanalytical Methods | Lifetime | 630 | PS 1 | 91.53 |
| Advances in Oncology and Radiotherapy | Lifetime | 643 | PS 1 | 90.39 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 1 | PS 1 | 99.97 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 2 | PS 1 | 99.98 |
| Genetic factors in colorectal cancer | 2021-2025 | 4 | PS 1 | 99.87 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 7 | PS 1 | 99.65 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 101 | PS 1 | 99.59 |
| Cancer Treatment and Pharmacology | 2021-2025 | 23 | PS 1 | 99.53 |
| Cancer Genomics and Diagnostics | 2021-2025 | 99 | PS 1 | 99.18 |
| Melanoma and MAPK Pathways | 2021-2025 | 13 | PS 1 | 99.45 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 124 | PS 1 | 99.20 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 131 | PS 1 | 98.61 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 78 | PS 1 | 98.00 |
| Colorectal and Anal Carcinomas | 2021-2025 | 61 | PS 1 | 97.45 |
| HER2/EGFR in Cancer Research | 2021-2025 | 76 | PS 1 | 98.74 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 231 | PS 1 | 95.82 |
| Peptidase Inhibition and Analysis | 2021-2025 | 281 | PS 1 | 94.15 |
| Cancer Research and Treatments | 2021-2025 | 290 | PS 1 | 88.95 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 423 | PS 1 | 89.48 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 988 | PS 1 | 90.97 |
| Advanced Breast Cancer Therapies | 2021-2025 | 754 | PS 2 | 86.46 |
| Fibroblast Growth Factor Research | 2021-2025 | 186 | PS 1 | 82.25 |
| Cancer Mechanisms and Therapy | 2021-2025 | 551 | PS 1 | 78.93 |
| Advances in Oncology and Radiotherapy | 2021-2025 | 584 | PS 1 | 76.11 |
